Arndt Vogel

Clinician-Scientist, ESMO Ambassador, focussed on Liver Cancer & Precision Oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪

[Arndt Vogel @ArndtVogel]

🔥great news🔥
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
https://t.co/u4Mr4ijEcu
👉expanding options for patients with FGFR2 fusions!
@myESMO @ASCO @ILCAnews @EASLedu

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Precision oncology in GI-cancer: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance
Seminars in Cancer Biology
👉PO is fascinating , but complex
👉No magic bullet, much to consider: vertical & sequential pathway inhibitions, persister & resistance mechanisms, rechallenge...
Our thoughts👇
https://t.co/T2AA1lAlqw

[JeanBonBeurre #KaneBallonDor @JeanBonBeurreL]

Les ambiances en Allemagne sont juste INJOUABLE

Quel régal de revoir Schalke en Bundesliga

[Arndt Vogel @ArndtVogel]

🔥Great news🔥

[Arndt Vogel @ArndtVogel]

STRIDE, with or without Lenva, combined with TACE in HCC: EMERALD-3 pts 3 study
@LancetOncology
https://t.co/3PE3B3mdz0
👉Interesting efficacy with STRIDE
👉Lenvatinib disappointing
🧐we need to define the right population for the combination
@myESMO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced HCC (TALENTOP): a multicentre phs 3 trial
@TheLancet
https://t.co/e2Zm4vbRdK
👉supports neoadjuvant concepts in HCC
👉response adopted treatment
@myESMO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Long-term outcomes of atezolizumab–bevacizumab in unresectable HCC: A real-world study
@HEP_Journal
https://t.co/EQqUZMCjlR
👉Liver decompensation in 14.1%
👉14.9% underwent surgical/ locoregional treatments
🧐multidisciplinary team is key
@myESMO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Satellite lesions vs intrahepatic metastasis in multifocal iCCC: Prognostic impact and genomic profiling
@HEP_Journal
https://t.co/PLHIy9oUCQ
👉SL & IM clonally derived from the primary > metastatic progression with poor long-term survival
@myESMO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine–cisplatin: A prospective observational cohort study
@HEP_Journal
https://t.co/5wG13SsnbP
👉Interesting activity, but we need to identify predictive biomarkers
@myESMO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Beyond rejection risk: Identifying ideal candidates for pretransplant immune checkpoint inhibitors for HCC
Liver Transplantation
https://t.co/OUDQBkW5tW
👉ICI before TX is feasible, but we need to better define timing & candidates
@myESMO @EASLnews @ILCA

[Arndt Vogel @ArndtVogel]

ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer
@Annals_Oncology
https://t.co/YzKDr6M392
👉pan-RAS(ON) inhibitor daraxonrasib included in second-line therapy
@myESMO

[Arndt Vogel @ArndtVogel]

Liquid Biopsies for Cancer
A Translational Science Review
@JAMAOnc
https://t.co/uuyi38Lovb
@myESMO

[Arndt Vogel @ArndtVogel]

[ 177 Lu]Lu-DOTA-TATE plus long-acting octreotide in newly diagnosed, advanced, grade 2–3, gastroenteropancreatic NEN: preplanned & post-hoc efficacy from NETTER-2 trail
https://t.co/PoyMRnxMZs
@eClinicalMed
👉support the use of first-line 177Lu-DOTATATE
@ASCO @myESMO

[Arndt Vogel @ArndtVogel]

Early Outcomes of Histotripsy for Liver Tumors in US Clinical Practice
@JAMANetworkOpen
https://t.co/1wPr0dSOAO (
👉Some many patients asking about this "safe" treatment
👉972 pts > 30-day mortality 11.1%
🤨very concerning, too much hype, we need more data
@myESMO @ASCOPost @EASLnews

[Arndt Vogel @ArndtVogel]

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02
@ESMO_Open
https://t.co/vu6Ns3qWOj
👉BTC: ORR 22.0%, 56% in HER2 IHC 3+, mOS 7mo
🧐NGS upfront key, IHC for Her2
@myESMO @ASCOPost @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

TACE Plus Thermal Ablation in Unresectable HCC
Phase 3 TORCH Randomized Clinical Trial
@JAMAOnc
https://t.co/Qi1UIX00Fl
👉Sequential TACE and thermal ablation for patients with liver-confined unresectable HCC improved survival compared with TACE alone
@myESMO @EASLnews @ILCAnews

[LARVOL @Larvol]

Top Trending GI Cancer Oncologists in July 2026, curated by @Larvol CLIN ranked by views on oncologists' posts on 𝕏.

Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @Aiims1742 | @Erman_Akkus | @DraMartinezLago | @ArndtVogel | @GIMedOnc | @DrAngelaLamarca | @p_ciracimd | @NiuSanford | @KoheiShitara | @GillSharlene

[Arndt Vogel @ArndtVogel]

@drjamesgood @myESMO @ASCO @ILCAnews Certainly more SBRT, specifically in Toronto 😅

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Changing Treatment Landscape of HCC: A RW Analysis of Treatment Algorithms & Outcomes of Patients over 10 Years
👉less use of TACE, more SIRT & systemic 💊
🫤but overall outcome still poor
👇my author link
https://t.co/4OQzLhikNa
@myESMO @ASCO @ILCAnews @EASLnews

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC
👉HCC management is shifting toward a personalized, multimodal continuum, a 🇨🇦 perspective
👇my author link
https://t.co/sbOxoPLAL3
@myESMO @asco